Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Seizert Capital Partners LLC

Seizert Capital Partners LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 8.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 469,940 shares of the biotechnology company's stock after buying an additional 34,875 shares during the period. Seizert Capital Partners LLC owned about 0.16% of Exelixis worth $12,195,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. State Board of Administration of Florida Retirement System raised its holdings in shares of Exelixis by 3.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 319,794 shares of the biotechnology company's stock valued at $7,589,000 after acquiring an additional 10,399 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Exelixis during the 1st quarter valued at about $1,216,000. Intech Investment Management LLC increased its stake in Exelixis by 155.8% during the 1st quarter. Intech Investment Management LLC now owns 100,039 shares of the biotechnology company's stock worth $2,374,000 after buying an additional 60,925 shares during the period. Covestor Ltd boosted its holdings in Exelixis by 39.4% in the first quarter. Covestor Ltd now owns 7,218 shares of the biotechnology company's stock valued at $171,000 after purchasing an additional 2,040 shares during the period. Finally, Seven Eight Capital LP raised its holdings in Exelixis by 234.2% in the first quarter. Seven Eight Capital LP now owns 75,661 shares of the biotechnology company's stock valued at $1,795,000 after acquiring an additional 53,024 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Activity at Exelixis

In related news, Director George Poste sold 30,000 shares of Exelixis stock in a transaction on Friday, November 1st. The stock was sold at an average price of $34.00, for a total value of $1,020,000.00. Following the transaction, the director now owns 169,020 shares in the company, valued at approximately $5,746,680. This trade represents a 15.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Dana Aftab sold 1,162 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the sale, the executive vice president now directly owns 498,945 shares of the company's stock, valued at $15,666,873. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 248,148 shares of company stock valued at $8,042,547. Company insiders own 2.85% of the company's stock.

Exelixis Stock Down 1.7 %

Shares of EXEL traded down $0.60 on Friday, reaching $34.45. The stock had a trading volume of 2,867,787 shares, compared to its average volume of 2,540,276. Exelixis, Inc. has a twelve month low of $19.20 and a twelve month high of $36.60. The firm has a market capitalization of $9.84 billion, a PE ratio of 22.08, a PEG ratio of 0.88 and a beta of 0.51. The firm has a 50-day moving average of $29.04 and a 200 day moving average of $25.15.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same quarter in the prior year, the company earned $0.10 earnings per share. Exelixis's revenue was up 14.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Exelixis, Inc. will post 1.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EXEL has been the topic of a number of recent analyst reports. BMO Capital Markets increased their price objective on shares of Exelixis from $29.00 to $36.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Stephens raised their price target on Exelixis from $23.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. Stifel Nicolaus upped their target price on shares of Exelixis from $26.00 to $30.00 and gave the company a "hold" rating in a report on Wednesday, October 16th. JMP Securities reiterated a "market outperform" rating and issued a $29.00 target price on shares of Exelixis in a research note on Friday, October 11th. Finally, Morgan Stanley upped their price target on Exelixis from $26.00 to $28.00 and gave the stock an "equal weight" rating in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $31.44.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.